Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   29 Trials   29 Trials   4783 News 


«12...2526272829303132333435...5960»
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. (Pubmed Central) -  Sep 5, 2021   
    Importantly, complement inhibition with eculizumab has shown beneficial effects in DHTR. Given the unmet clinical need of novel therapeutics in SCD, our review summarizes current understanding of (a) complement system for the clinician, (b) complement activation in SCD both in asymptomatic state and severe clinical manifestations, (c) probable underlying mechanisms of complement activation in SCD, and (d) new therapeutic perspective of complement inhibition.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Clinical, Journal:  Off-label drug use in pediatric patients: a comparative analysis with nationwide routine prescription data. (Pubmed Central) -  Aug 21, 2021   
    Though OLDU applications is overall consistent with routine clinical practice in terms of demographics and institutional capacity, substantial variations exist regarding main drug classes and diseases. Our findings are expected to shed light on interventions focused on improving `indicated` pediatric use of drugs currently applied as off-label.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Journal:  Prothrombotic immune thrombocytopenia after COVID-19 vaccination. (Pubmed Central) -  Aug 12, 2021   
    It is characterized by thrombocytopenia and anti-PF4 antibodies binding to platelets in AZD1222-dependent manner. Initial clinical experience suggests a risk of unusual and severe thromboembolic events.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Complement Inhibition for Prevention of Antibody-mediated Rejection in Immunologically High-risk Heart Allograft Recipients. (Pubmed Central) -  Aug 11, 2021   
    P3
    In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant...In a pre-specified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR=0.36, 95%CI=0.14-0.95, p=0.032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] NEW TREATMENTS IN NEUROINFLAMMATORY DISORDERS (Topic D) -  Aug 6, 2021 - Abstract #WCN2021WCN_774;    
    Likewise, tocilizumab which targets interleukin 6 is an increasingly interesting option in autoimmune encephalitis patients who fail rituximab, and other neuroinflammatory disodrers which are not 'autoantibody mediated'. Neuroinflammation can take other forms, and there is increasing interest in epigenetic immune dysfunction, and therefore the use of epigenetic therapeutics, which opens up the potential opportunity of repurposong drugs which are epigenetic modulators such as ketogenic diet, cannabidiol, and valproate, amongst many.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Parallel Industry Symposium 01 (Not Included In The Main Event CME/CPD Credit) (Industry 1) -  Aug 6, 2021 - Abstract #WCN2021WCN_414;    
    Session Description: This symposium aims to: -tSpread the knowledge of a pathophysiologic mechanism that not many clinicians know properly, but that is proven to be one of the trigger causes of NMOSD (Neuromyelitis Optica Spectrum Disorder) and gMG (generalized Myasthenia Gravis), two immune mediated rare neurological diseases. -tPresent data for eculizumab on both diseases and highlight innovation in therapeutic environment thanks to the discussion with experts.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy. (Pubmed Central) -  Aug 6, 2021   
    Prompt diagnosis is critical for survival and treatment necessitates withdrawal of the offending drug; however, many cases require further treatment including plasmapheresis, immunosuppression, and anticoagulation. In this article, we report a cutaneous biopsy-proven case of tacrolimus-induced DITMA, which was successfully treated with eculizumab after failing the conventional standard of care.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND LIVER TRANSPLANTATION, A NEW PARADIGM. (Pubmed Central) -  Aug 6, 2021   
    In this way, liver cirrhosis secondary to PNH with secondary Budd-Chiari syndrome, goes from being a contraindication for LT to being one of the indications for it. There are few reported cases of transplantation in these patients, but they report good results as in this case(2-3).
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Complement factor I deficiency: A potentially treatable cause of fulminant cerebral inflammation. (Pubmed Central) -  Aug 4, 2021   
    These diagnostic challenges may mean that the CFI deficiency is being systematically under-recognized as a cause of fulminant cerebral inflammation. Complement inhibitory therapies (such as eculizumab) offer new potential treatment, underlining the importance of prompt recognition, and real-time whole exome sequencing may play an important future role.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. (Pubmed Central) -  Aug 4, 2021   
    P3
    This analysis demonstrates that eculizumab's long-term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
    [VIRTUAL] Current standard of care and new emerging treatments in NMOSD (Stream 7 Educational Sessions) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1401;    
    Classical immunosuppressive therapies (IST) such as azathioprine, mycophenolate mofetil with and without low-dose oral steroids showed efficacy in non-controlled trials and have been widely used in the past to reduce relapses...Subsequently, after successful clinical trials, three monoclonal antibodies have been approved for the treatment of AQP4-IgG positive NMOSD since 2019: the C5 complement inhibitor eculizumab, the IL-6 receptor antibody satralizumab and the anti-CD19 antibody inebilizumab...IST as well as rituximab and tocilizumab as off-label therapies are usually used for those patients. In light of the new therapeutic landscape the current standard of care in NMOSD is reviewed and treatment recommendations discussed for AQP4-IgG positive and negative NMOSD patients in this educational session.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    [VIRTUAL] Management issues (Stream 6 Educational Sessions) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_34;    
    In many pediatric centers, oral prednisone, starting at 1-2 mg/kg/day on a tapering schedule is reserved for patients failing to demonstrate full or near-complete resolution of symptoms with IV treatment...Treatment of relapsing MOGAD patients includes monthly IVIg (particularly in children), anti-CD20 directed therapies, mycophenolate mofetil, and there exists emerging interest in the potential role for therapies recently studied for NMOSD (anti-IL6 treatments or eculizumab)...Whether relapsing MOGAD is a chronic life-time disease or a protracted but ultimately transient neuro-inflammatory disorder remains to be fully determined. Treatment strategies for acute attacks and for relapsing disease will be reviewed in more depth in the presentation, as well as the results of a recent international survey of clinical care models for treatment of pediatric and adult MOGAD.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. (Pubmed Central) -  Aug 1, 2021   
    Membrane attack complex (C5b-9) deposition on endothelial cells in culture exposed to plasma from patients during the acute phase of the disease suggests complement overactivation as a mechanism of potential endothelial damage in three out of four patients. If confirmed in larger cohorts, C5b-9 evaluation will allow early identification of patients who could benefit from complement blockade and treatment monitoring.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. (Pubmed Central) -  Jul 28, 2021   
    Concentrations in each placenta of unbound eculizumab were 41 ± 3 and 45 ± 4 μg/g tissue, of C5-eculizumab 19 ± 2 and 32 ± 3 μg/g, and of C5 20 ± 3 and 30 ± 2 μg/g (mean±SD, in three tissue samples per placenta). Placental levels of unbound eculizumab were higher than those of C5-eculizumab complexes, while maternal concentrations were approximately equal, suggesting selective transport of unbound eculizumab across the placenta.